Peter C L Beverley
Overview
Explore the profile of Peter C L Beverley including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
1504
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Allen C, Beverley P, Collin M, Diamond E, Egeler R, Ginhoux F, et al.
Nat Immunol
. 2019 Dec;
21(1):1-7.
PMID: 31831887
No abstract available.
2.
Verreck F, Tchilian E, Vervenne R, Sombroek C, Kondova I, Eissen O, et al.
Tuberculosis (Edinb)
. 2017 Apr;
104:46-57.
PMID: 28454649
M.bovis BCG vaccination against tuberculosis (TB) notoriously displays variable protective efficacy in different human populations. In non-human primate studies using rhesus macaques, despite efforts to standardise the model, we have...
3.
Dean G, Clifford D, Whelan A, Tchilian E, Beverley P, Salguero F, et al.
PLoS One
. 2015 Nov;
10(11):e0142270.
PMID: 26544594
The incidence of bovine tuberculosis (bTB) in the GB has been increasing since the 1980s. Immunisation, alongside current control measures, has been proposed as a sustainable measure to control bTB....
4.
Beverley P, Ruzsics Z, Hey A, Hutchings C, Boos S, Bolinger B, et al.
J Immunol
. 2014 Jul;
193(5):2306-16.
PMID: 25070842
Tuberculosis remains a global health problem so that a more effective vaccine than bacillus Calmette-Guérin is urgently needed. Cytomegaloviruses persist lifelong in vivo and induce powerful immune and increasing ("inflationary")...
5.
Tchilian E, Ronan E, de Lara C, Ni Lee L, Franken K, Vordermeier M, et al.
PLoS One
. 2011 Nov;
6(11):e27477.
PMID: 22110657
Background: BCG, the only licensed vaccine against tuberculosis, provides some protection against disseminated disease in infants but has little effect on prevention of adult pulmonary disease. Newer parenteral immunization prime...
6.
Ni Lee L, Ronan E, de Lara C, Franken K, Ottenhoff T, Tchilian E, et al.
Infect Immun
. 2011 Jun;
79(8):3328-37.
PMID: 21628524
Convincing correlates of protective immunity against tuberculosis have been elusive. In BALB/c mice, intranasal immunization with a replication-deficient recombinant adenovirus expressing Mycobacterium tuberculosis antigen 85A (adenovirus-85A) induces protective lower respiratory...
7.
Lee L, Baban D, Ronan E, Ragoussis J, Beverley P, Tchilian E
BMC Med Genomics
. 2010 Oct;
3:46.
PMID: 20942964
Background: Immunization of BALB/c mice with a recombinant adenovirus expressing Mycobacterium tuberculosis (M. tuberculosis) antigen 85A (Ad85A) protects against aerosol challenge with M. tuberculosis only when it is administered intra-nasally...
8.
Ronan E, Ni Lee L, Tchilian E, Beverley P
Vaccine
. 2010 Jun;
28(32):5179-84.
PMID: 20558252
Intra-nasal administration of a recombinant adenovirus expressing Mycobacterium tuberculosis antigen 85A (Ad85A) has been shown to provide protection against challenge with M. tuberculosis. However the role of the upper respiratory...
9.
Davies M, Bayry J, Tchilian E, Vani J, Shaila M, Forbes E, et al.
PLoS One
. 2009 Dec;
4(11):e8084.
PMID: 20011659
Background: Adjuvants enhance or modify an immune response that is made to an antigen. An antagonist of the chemokine CCR4 receptor can display adjuvant-like properties by diminishing the ability of...
10.
Ronan E, Ni Lee L, Beverley P, Tchilian E
PLoS One
. 2009 Dec;
4(12):e8235.
PMID: 20011050
Background: In pulmonary Mycobacterium tuberculosis (Mtb) infection, immune responses are delayed compared to other respiratory infections, so that antigen-specific cells are not detected in the lungs earlier than day 14....